XML 25 R12.htm IDEA: XBRL DOCUMENT
v3.21.2

Licensed rights and other intangible assets | 9 Months Ended
--- | ---
Sep. 30, 2021
Goodwill And Intangible Assets Disclosure [Abstract] |
Licensed rights and other intangible assets | 6.Licensed rights and other intangible assets The following provides information about our license rights and other intangible assets, net (in thousands):
|  | September 30, 2021 |  |  | December 31, 2020 |
|  | Gross |  |  |  |  |  |  |  |  |  |  | Gross |  |  |  |  |  |  |  |  |
|  | Carrying |  |  | Accumulated |  |  |  |  |  |  | Carrying |  |  | Accumulated |  |  |  |  |
|  | Amount |  |  | Amortization |  |  | Net |  |  | Amount |  |  | Amortization |  |  | Net |
Licensed rights and intangible assets subject to amortization: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License rights |  | $ | 40,000 |  |  | $ | 6,070 |  |  | $ | 33,930 |  |  | $ | 40,000 |  |  | $ | 3,803 |  |  | $ | 36,197 |
Hormone therapy drug patents |  |  | 4,732 |  |  |  | 985 |  |  |  | 3,747 |  |  |  | 4,045 |  |  |  | 749 |  |  |  | 3,296 |
Hormone therapy drug patents applied and pending approval |  |  | 1,596 |  |  |  | — |  |  |  | 1,596 |  |  |  | 1,629 |  |  |  | — |  |  |  | 1,629 |
License rights and other intangible assets subject to amortization |  |  | 46,328 |  |  |  | 7,055 |  |  |  | 39,273 |  |  |  | 45,674 |  |  |  | 4,552 |  |  |  | 41,122 |
Intangible assets not subject to amortization: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Trademarks/trade name rights |  |  | 344 |  |  |  | — |  |  |  | 344 |  |  |  | 323 |  |  |  | — |  |  |  | 323 |
License rights and other intangible assets, net |  | $ | 46,672 |  |  | $ | 7,055 |  |  | $ | 39,617 |  |  | $ | 45,997 |  |  | $ | 4,552 |  |  | $ | 41,445 |
Licensed rights We recorded amortization expense related to the exclusive license rights agreement (the “Population Council License Agreement”) with Population Council of $0.8 million for the three months ended September 30, 2021 and 2020, and $2.3 million for the nine months ended September 30, 2021 and 2020.Other intangible assets As of September 30, 2021, we had a total of 87 patents, of which 46 were domestic. As of December 31, 2020, we had a total of 77 patents, of which 38 were domestic. We recorded amortization expense related to patents of $0.1 million for the three months ended September 30, 2021 and 2020, and $0.2 million for the nine months ended September 30, 2021 and 2020, respectively. We use a combination of qualitative and quantitative factors to assess licensed rights and intangible assets for impairment. As a result of performing these assessments, we determined that no impairment existed as of September 30, 2021 and, therefore, recorded no write-downs to any of our licensed rights and other intangible assets. However, during the nine months ended September 30, 2020, we wrote off $584,509 in costs related to trademarks and patents.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI http://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration